A Study of NTRX-07 in Participants With Alzheimer's Disease

Launched by NEUROTHERAPIA, INC. · Jun 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medicine called NTRX-07, which is being tested in people with mild cognitive impairment (MCI) or mild to moderate Alzheimer’s disease (AD). The main goal is to see if the drug is safe and well-tolerated when taken daily for 28 days. Researchers will also look at how the body processes the medicine by measuring its levels in the blood and spinal fluid. Although the focus is on safety, the study will also explore if NTRX-07 has any positive effects on memory, thinking, and brain health.

People eligible for this study are between 65 and 80 years old, have been diagnosed with MCI or mild to moderate Alzheimer’s, and must have a caregiver who can help with the study. Participants will need to complete tests like brain scans and memory assessments before starting. During the study, they will take either NTRX-07 or a placebo (a pill without medicine) every day for 28 days, visit the study center regularly for check-ups, and have tests to monitor safety and brain function. There will also be a follow-up visit a week after treatment ends. This study is important because it helps researchers understand if NTRX-07 could be a safe and helpful new treatment option for people with Alzheimer’s disease.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • 1. Participants must be 65-80 years of age inclusive, at the time of signing the informed consent.
• • 2. Clinical Dementia Rating (CDR) of 0.5 - 2.0; and education-adjusted Logical Memory II scores consistent with MCI or mild to moderate AD (\<1.5 SD below mean cutoff). MMSE 12-26
• • 3. pTau 217 consistent with AD, or recent amyloid test panel within 2 years. The test must be after any previous participation in an anti-amyloid MAB trial.
• • 4. Participants who have been in a previous amyloid-directed MAB study must have a negative ARIA report after the study.
• • 5. Confirmed medical documentation of AD symptoms onset at age 60 or later.
• • 6. No active depression and a Geriatric Depression Score of \< 6.
• • 7. No change in acetylcholinesterase inhibitors or memantine for the previous six months and is not expected to start an acetylcholinesterase inhibitor during the duration of the study.
• • 8. Living at home, with a reliable caregiver who sees them at least 3 times/week for 10 hours or more and can oversee the administration of the study drug.
• • 9. Provide written informed consent and willingness as documented by a signed informed consent form; responsible caregiver must also provide written consent.
• • 10. Body weight within 55-110 kg and body mass index (BMI) within the range 18-35 kg/m2 (inclusive)
• 11. Male or Female • Male participants: Male participants are eligible to participate if they agree to the following during the intervention period and for at least 90 days, after the last dose of study intervention:
• Refrain from donating sperm PLUS, either:
• • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent ba sis) and agree to remain abstinent.
• • OR
• • Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.
• • Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person.
• • Female participants: Must be a woman of nonchildbearing potential (WONCBP) (at least two years post-menopause or surgically sterile).
• • Exclusion Criteria
• • 1. Reported history or presence of clinically significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data. Participants with stable, well-controlled conditions may be accepted upon review by the investigator and sponsor.
• • 2. Change of more than 2 points from screening MMSE to baseline MMSE, or discrepancy in disease classification between MMSE, and Trail Making test.
• • 3. Diagnosis of a dementia-related CNS disease other than AD (eg, Parkinson's Disease, Huntington's Disease, frontotemporal dementia, multi-infarct dementia, dementia with Lewy bodies, normal pressure hydrocephalus)
• • 4. Cannot tolerate spinal puncture procedure for cerebral spinal fluid (CSF).
• • 5. Anticoagulation therapy that would contraindicate spinal puncture procedure for cerebral spinal fluid (CSF).
• • 6. Any contraindication to MRI (per facility standard of care).
• • 7. Major structural brain disease by reported history or chart review (e.g., ischemic infarcts, subdural hematoma, hemorrhage, hydrocephalus, brain tumors, multiple subcortical ischemic lesions, severe mi- microangiopathic disease, volume loss disproportionate for age or a single lesion in a critical region e.g., thalamus, hippocampus).
• • 8. Findings on MRI demonstrating intracranial pathology as an alternative cause for cognitive impairment
• • 9. Any other reported history of central nervous system (CNS) trauma (e.g., contusion), or infections (e.g., human immunodeficiency virus \[HIV\], syphilis), that present active or residual effects on cognitive function.
• • 10. Reported history of seizures, with the exception of childhood febrile seizures or metabolic seizures where the underlying etiology has resolved, and the participant has been seizure-free without treatment for at least 2 years.
• • 11. Autoimmune disorders, active infections or other disorders, including the use of immunosuppressants, that may affect the subject's immune system.
• • 12. Reported current or chronic history of clinically significant liver disease. This includes but is not limited to hepatitis virus infections, drug- or alcohol-related liver disease, nonalcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease, α-1 antitrypsin deficiency, primary biliary cholangitis, primary sclerosing cholangitis, or any other liver disease considered clinically significant by the investigator.
• • 13. Reported hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) that are deemed clinically significant by the PI or medical monitor.
• • 14. Abnormal TSH, fT3 or fT4 at baseline screening. Subjects with known hypothyroidism or hyperthyroidism should be stable on treatment for 6 months prior to starting study and not anticipated to require any type of dose adjustment during the course of the study.
• • 15. Reside in a nursing home or assisted care facility with the need for direct continuous medical care and nursing supervision. Participant may reside in such facilities provided continuous direct medical care is not required.
• • 16. Subjects who require close or continual monitoring for self care or basic activities of daily living.
• • 17. Subjects with history of psychiatric conditions such as schizophrenia and or bipolar disorder
• • 18. Any reported history from the patient, family, or on supplied chart re- view or current suicide risk
• • 19. Patients may continue prior concomitant medications at the same sta ble dose. Drugs with potential interactions are detailed in the investi gator's brochure. Participants receiving drugs with strong interactions should be excluded where the drug in question cannot be safely stopped for an appropriate washout period pre-study and until 7 days after the last dose of study medication (completion of the post-study safety visit).
• • 20. Reported treatment with biological agents in the 3 months prior to dosing in this study, or within 5 half-lives of the biological agent prior to dosing..
• • 21. Current enrollment or past participation within the last 30 days before signing of consent in any other clinical study involving an investiga- tional study intervention.
• 22. Clinical laboratory findings outside the normal range and determined by the investigator or medical monitor to be clinically significant. These include but are not limited to:
• • 1. Alanine transaminase (ALT) or aspartate transaminase (AST) \>1.5 x upper limit of normal (ULN)
• • 2. Total bilirubin \>1.5 x ULN (isolated bilirubin \>1.5 x ULN is acceptable if total bilirubin is fractionated and direct bilirubin \<35%)
• • 3. QTcF \>450 msec for male participants or \>470 msec for female participants
• • 4. Positive drug/alcohol screen
• • 23. Reported sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study
• • 24. Reported regular use of known drugs of abuse within the past 3 years.
• • 25. Inability to withhold CNS medications (e.g., benzodiazepines, stimulants) for 3 half-lives of the drug prior to cognitive testing and EEG administration.
• • 26. Presence of any contraindication to venous blood sampling for pharmacokinetic analyses.
• • 27. Positive SARS-CoV-2 test, hepatitis panel (including hepatitis B sur face antigen \[HBsAg\] or hepatitis C virus antibody \[anti-HCV\]), a positive HIV antibody screen or positive syphilis test